"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."
PRESIDENT, US ONCOLOGY, JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
"I am excited about Janssen’s aspirational vision to eliminate cancer. With targeted therapies and immunotherapies, cancer treatment can be more effective and less toxic, enabling individuals to manage their disease while also maintaining their quality of life."
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.